A phase 2b/3 trial of Gilead Sciences' and Galapagos’ filgotinib in ulcerative colitis patients has met its primary endpoint. Yet, with the lower dose missing a key endpoint, investors responded negatively to the data, sending shares in Galapagos down 7% in early trading in Amsterdam.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,